Dulaglutide Biosimilar (Salubris)

度拉糖肽生物类似药（信立泰）

Report date: 2026/02/03 20:00:14

Base Information

Drug NameDulaglutide Biosimilar (Salubris)

Drug Alias NameRecombinant GLP-1-Fc fusion protein重组胰高血糖素样肽-1-Fc融合蛋白注射液GLP.FC fusion proteinSAL015SAL-015

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionGlucagon-like peptide 1 receptor agonists

TargetsGlucagon-like peptide 1 receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPending

China Registration ClassN/A

Active IndicationsDiabetes Mellitus

Inactive IndicationsDiabetes Mellitus, Type 2

ATC CodeA10BJ02